menu

ACC 2024: VOYAGER PAD Part 2

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Key Advances in Heart Health: Insights From the American College of Cardiology 2024 Scientific Sessions 

ACC 2024: VOYAGER PAD Part 2

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
0.75 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.  

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.  

    Faculty: 
    Marc P. Bonaca, MD, MPH 
    Director of Vascular Research
    Associate Professor of Medicine
    University of Colorado School of Medicine
    Aurora, CO 

    Dr. Bonaca has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AstraZeneca, Bayer, Merck, Roche Diagnostics 

    Daniel Gaudet, MD, PhD 
    Professor of Medicine 
    University de Montreal
    Montreal, Quebec, Canada 

    Dr. Gaudet has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Contracted Research/Consulting Fees: Alnylam, Amgen, Applied Therapeutics, Arrowhead, Boehringer Ingelhein, Chiesi (Amryt), CRISPR Therapeutics, Eli Lilly, Esperion, Ionis, Kowa, New Amsterdam Pharma, Novartis, NovoNordisk, Pfizer, Regeneron, Sanofi, Ultragenyx, Uniqure, Verve Therapeutics 

    Manesh R. Patel, MD 
    Chief, Division of Cardiology
    Co-Director Duke Heart Center
    Duke Clinical Research Institute, Duke University
    Durham, NC 

    Dr. Patel has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Bayer, Janssen, Novartis
    Contracted Research: AstraZeneca, Bayer, Janssen, Mytomy, Procyrion 

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has nothing to disclose.  
    • Amanda Hilferty has nothing to disclose. 
    • Tim Person has nothing to disclose.  
    • Carry Pesch has nothing to disclose. 
    • Katie Sheridan, PhD, has nothing to disclose. 
    • Will Uptegraph has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:  

    • Evaluate recent practice-changing data that can be applied to practice and patients. 
    • Apply recently presented data into clinical practice to expand treatment options and improve outcomes for patients. 
    • Discuss new data on novel agents and therapeutic approaches for patients with application in the community setting. 
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, primary care physicians, and emergency medicine and endocrinologists/lipid specialists. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.  

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.  

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 0.75 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity. 

     
    Global Learning Collaborative (GLC) designates this activity for 0.75 contact hours/0.075 CEUs of pharmacy contact hours.1 The Universal Activity Number for this program is JA0006235-0000-24-050-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).   

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by independent educational grants from Arrowhead Pharmaceuticals Inc. and Janssen Scientific Affairs, LLC. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of TotalCME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule22 Jun 2024